

06-10-05

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Kuliopulos et al.
SERIAL NUMBER: 11/075,645 EXAMINER : Not Yet Assigned
FILING DATE: March 7, 2005 ART UNIT : Not Yet Assigned
FOR: G PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS AND
ANTAGONISTS AND METHODS OF ACTIVATING AND
INHIBITING GPCR USING THE SAME

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18475-034 DIV. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

IA Beattie

Ingrid A. Beattie, Reg. No. 42,306
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623


Tel: (617) 542-6000

Fax: (617) 542-2241

Date: June 9, 2005

Express Mail Label No.: EV 475171472 US
Date of Deposit: June 9, 2005

Attorney Docket No.: 18475-034 DIV



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Kuliopulos et al.
SERIAL NUMBER: 11/075,645 EXAMINER : Not Yet Assigned
FILING DATE: March 7, 2005 ART UNIT : Not Yet Assigned
FOR: G PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS AND
ANTAGONISTS AND METHODS OF ACTIVATING AND
INHIBITING GPCR USING THE SAME

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. Copies of the references (*) are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 09/841,091, filed April 23, 2001 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

APPLICANT: Kuliopulos et al.
U.S.S.N.: 11/075,645

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 18475-034 DIV.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: June 9, 2005

TRA 2043430v1

Express Mail No.: EV 475171472 US

Date of Deposit: June 9, 2005

Page 1 of 1

Attorney Docket No.: 18475-034 DIV

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	11/075,645
	Filing Date	March 7, 2005
	First Named Inventor	Kuliopulos
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18475-034 DIV

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	6,111,076	8/29/00	Fukusumi, et al.			9/30/98
	*A2	6,096,868	8/1/00	Halsey, et al.			6/8/99
	*A3	5,925,549	7/20/99	Hsueh, et al.			8/14/97
	*A4	6,162,808	12/19/00	Kindon, et al.			5/18/98
	*A5	5,747,267	5/5/98	Mulvihill, et al.			5/31/95

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C38	Coughlin et al. <i>J. Clin. Invest.</i> , 111(1):25-27 (2003)
	*C39	Tarasova <i>J. Biol. Chem.</i> , 274:34911-34915 (1999)
	*C40	Vergnolle et al. <i>TRENDS Pharma. Sci.</i> , 22:146-152

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/841,091, filed April 23, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2043276v1